# DeLLphi-303 (NCT05361395)

> First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05361395
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Extensive Stage Small Cell Lung Cancer
- Interventions: Tarlatamab; Carboplatin; Etoposide; Atezolizumab; Durvalumab
- Enrollment: 184
- Primary outcome: Number of Participants with a Dose Limiting Toxicity (DLT)
- Primary outcome: Number of Participants with Treatment-emergent Adverse Events (TEAE)
- Primary outcome: Number of Participants with Treatment-related Adverse Events
- Primary outcome: Number of Participants with Clinically Significant Changes in Vital Signs
- Primary outcome: Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements
- Primary outcome: Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 50
- Podcasts: 23
- YouTube: 22

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dellphi-303-nct05361395

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05361395", "email": "<work email>"}; the inbox owner confirms by the emailed link.